Related Experiment Video
Updated: Aug 6, 2026

Modeling Multiple Sclerosis in the Two Sexes: MOG35-55-Induced Experimental Autoimmune Encephalomyelitis
Published on: October 13, 2023
Tailoring disease-modifying therapy approaches across multiple sclerosis sub-populations
Albert Aboseif1, Burcu Zeydan2, Nabeela Nathoo3
1Division of Multiple Sclerosis and Autoimmune Neurology, Department of Neurology, Mayo Clinic, Rochester, MN, USA; Center for Multiple Sclerosis and Autoimmune Neurology, Mayo Clinic, Rochester, MN, USA.
Disease-modifying therapies (DMTs) for multiple sclerosis (MS) show promise, but optimal selection requires considering diverse patient populations, including race, age, and identity. Further research is needed to address knowledge gaps in sub-population treatment approaches.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Disease-modifying therapies (DMTs) have significantly advanced multiple sclerosis (MS) management.
- Current treatment guidelines may not universally apply to all patient demographics.
- Individualized care is crucial for people with MS (pwMS).
Purpose of the Study:
- To review contemporary evidence on DMT selection for diverse MS populations.
- To explore factors influencing DMT choice across different life stages and backgrounds.
- To identify gaps in current knowledge regarding DMT use in MS sub-populations.
Main Methods:
- Narrative review of current scientific literature.
- Synthesis of data from clinical trials, post-hoc analyses, and observational studies.
- Focus on evidence related to race, ethnicity, reproductive status, age, and sexual and gender identity.
Main Results:
- Evidence suggests DMT efficacy and tolerability can vary across diverse pwMS.
- Specific data on DMT use in underrepresented racial/ethnic groups and LGBTQ+ individuals is limited.
- Age and reproductive status are key considerations in DMT selection.
Conclusions:
- DMT selection in MS must be personalized, considering a patient's unique background and life stage.
- Further research is essential to develop evidence-based treatment strategies for all MS sub-populations.
- Addressing disparities in DMT research and application is critical for equitable MS care.
More Related Videos
10:46A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
09:38Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
Published on: September 12, 2016
Related Concept Videos
Multiple Sclerosis l: Introduction
Therapeutic Drug Monitoring: Affecting Factors
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Dosage Regimen: Individualization
Pharmacogenomics: Identification of New Drug Targets
Therapeutic Drug Monitoring: Drug Analysis Methods